MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/lary.20807

Медицинская библиотека · The Laryngoscope · 2010

Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center.

Buckmiller Lisa M, Munson Patrick D, Dyamenahalli Umesh, Dai Yuemeng, Richter Gresham T

Сравнительное исследованиеСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVES/HYPOTHESIS: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas. Systematic examination of this treatment in a tertiary care setting has not been described. This study explores the impact of propranolol on both proliferative and involuting hemangiomas at a tertiary vascular anomalies center.

STUDY

DESIGN

Retrospective single institution review.

MATERIALS AND

METHODS

We reviewed children treated with propranolol for problematic hemangiomas followed by a blinded prospective analysis of serial photographs taken during the course of their therapy. Parental questionnaires were obtained to evaluate perceived therapeutic response and complications to oral propranolol.

RESULTS

Thirty-two children with complete photo documentation were treated with oral propranolol for infantile hemangiomas between September 2008 and June 2009. Twenty-seven patients began therapy during the proliferative phase of their lesions (mean age, 4.9 months), whereas five patients began during the involutional phase (mean age, 19.4 months). Ninety-seven percent of patients displayed improvement in the quality of their hemangiomas during propranolol therapy. Patients were determined to be excellent responders (n = 16, 50%), partial responders (n = 15, 47%), or nonresponders (n = 1, 3%). Partial and nonresponders received adjuvant therapy (75%, laser therapy; 31%, steroid injections). Ten patients experienced minor but reportable side effects to propranolol, including somnolence (27.2%), gastroesophageal reflux (9.1%), respiratory syncytial virus exacerbation (4.5%), and rash (4.5%).

CONCLUSIONS

Propranolol may revolutionize the treatment of problematic hemangiomas that cause imminent functional or cosmetic sequelae. At therapeutic doses, propranolol is safe and effective in the majority of patients. Adjunctive therapies may still be required. Minor side effects, expected from beta-blocker therapy, are common but easily managed.

Для цитирования: Buckmiller Lisa M, Munson Patrick D, Dyamenahalli Umesh, Dai Yuemeng, Richter Gresham T. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center.. The Laryngoscope. 2010. DOI: 10.1002/lary.20807.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.